Thomas Pitts, MD
Endocrinology, Diabetes & Metabolism · Chicago, ILNPI 1730146671
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.3% of the total across 622 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 13.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $3,347 and has fallen 98.8% since, to $40 in 2025.
Across 622 payments — averaging $19.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- Boehringer Ingelheim$1K
- AstraZeneca$1K
- Lilly USA, LLC$953
- Mannkind Corporation$839
- Sanofi-aventis U.S. LLC$741
- plus $5K from 34 others
Across 11 payments — averaging $1531.53 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sanofi US Services Inc.$9K
- Amarin Pharma, Inc.$5K
- Lexicon Pharmaceuticals, Inc.$2K
What the payments were for
- Food & beverage$12,10899%
- Education$891%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 108 | $1,651 |
| Boehringer Ingelheim | 60 | $1,482 |
| AstraZeneca(2 entities) | 59 | $1,369 |
| Lilly USA, LLC | 45 | $953 |
| Mannkind Corporation | 41 | $839 |
| Sanofi-aventis U.S. LLC | 40 | $741 |
| Merck | 46 | $710 |
| AbbVie | 28 | $489 |
| Dexcom, Inc. | 17 | $401 |
| Corcept Therapeutics | 20 | $366 |
| Amgen(2 entities) | 21 | $356 |
| IBSA Pharma Inc. | 15 | $269 |
| Johnson & Johnson | 13 | $252 |
| Intuity Medical Inc | 8 | $238 |
| Medtronic | 3 | $231 |
| Xeris Pharmaceuticals, Inc. | 11 | $212 |
| Arbor Pharmaceuticals, Inc. | 13 | $200 |
| Sanofi Pasteur Inc. | 10 | $150 |
| Vivus LLC | 8 | $137 |
| Bayer | 6 | $136 |
| Lifescan, Inc. | 4 | $124 |
| Amarin Pharma, Inc. | 6 | $119 |
| Abbott | 6 | $106 |
| Pfizer | 5 | $88 |
| Shire North American Group Inc | 4 | $75 |
| Esperion Therapeutics, Inc. | 3 | $59 |
| Cequr Corporation | 2 | $59 |
| Novartis | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 3 | $44 |
| Tandem Diabetes Care, Inc. | 1 | $43 |
| Insulet Corporation | 2 | $40 |
| Azurity Pharmaceuticals, Inc. | 2 | $38 |
| Amneal Pharmaceuticals LLC | 2 | $35 |
| Aegerion Pharmaceuticals, Inc. | 2 | $30 |
| Amryt Pharma Holdings Ltd | 1 | $24 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $22 |
| Radius Health, Inc. | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $17 |
| Hikma Pharmaceuticals USA | 1 | $14 |
| Vistapharm, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,197 in reported general payments places this provider in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
See all endocrinology, diabetes & metabolism providers in Illinois →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RybelsusSemaglutide | 74 | $87,995 |
| JardianceEmpagliflozin | 83 | $78,765 |
| OzempicSemaglutide | 40 | $72,996 |
| FarxigaDapagliflozin Propanediol | 34 | $36,891 |
| MounjaroTirzepatide | 27 | $30,240 |
| EliquisApixaban | 23 | $24,597 |
| JanuviaSitagliptin Phosphate | 16 | $24,258 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 25 | $10,231 |
| Tresiba Flextouch U-200Insulin Degludec | 13 | $9,196 |
| JanumetSitagliptin Phos/Metformin Hcl | 11 | $8,646 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 13 | $7,020 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 40 | $5,800 |
| SynthroidLevothyroxine Sodium | 65 | $5,461 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 58 | $5,047 |
| HumalogInsulin Lispro | 14 | $3,086 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $1,651 | $160,992114 claims |
| Boehringer IngelheimJardiance | $1,482 | $78,76583 claims |
| AstraZenecaFarxiga | $1,369 | $36,89134 claims |
| Lilly USA, LLCMounjaro, Humalog | $953 | $33,32641 claims |
| MerckJanuvia, Janumet | $710 | $32,90427 claims |
| PfizerEliquis | $88 | $24,59723 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $741 | $7,02013 claims |
| AbbVieSynthroid | $489 | $5,46165 claims |
| Arbor Pharmaceuticals, Inc.Edarbi | $200 | $2,67711 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $35 | $1,562111 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 347 endocrinology, diabetes & metabolism providers in Illinois.
Other endocrinology, diabetes & metabolism in Chicago
- Wahid KassarChicago$884K
- George BakrisChicago$403K
- Wenyu HuangChicago$341K
- Silvana PannainChicago$226K
- Grazia AleppoChicago$162K
- Tamara VokesChicago$139K
- Emily SmithChicago$112K
- Antonio BiancoChicago$111K
- Aaron BenjaminChicago$105K
- David OyerChicago$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.